Reports from University of Toronto Provide New Insights into Chronic Pain (Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action).

This article focuses on a recent review from the University of Toronto examining the potential of serotonergic psychedelics—such as psilocybin, N,N-dimethyltryptamine (DMT), and Lysergic Acid Diethylamide (LSD)—as therapeutic agents for individuals with comorbid Major Depressive Disorder (MDD) and chronic pain. The review highlights that these conditions frequently co-occur and present greater clinical challenges than when occurring separately. It discusses putative mechanisms of psychedelics, including serotonergic modulation via the 5-HT2A receptor, anti-inflammatory effects, neuroplasticity, and psychological influences, suggesting a unified treatment approach. The authors advocate for future clinical trials to evaluate psychedelic-assisted therapies for this complex neuropsychiatric and medical comorbidity. [Extracted from the article]